BLUEJET · Healthcare · Biotechnology
Composite scorecard: 66/100 — Quality 100 · Growth 60 · Momentum 0
| Share price | ₹589.50 |
| Market cap | ₹7,031 Cr |
| P/E ratio | 24.0 |
| P/B ratio | 5.6 |
| ROE | 26.9% |
| ROCE | 35.0% |
| Dividend yield | 0.30% |
| Book value | ₹72.50 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2025 | ₹1,026 Cr | ₹305 Cr | 35.1% |
| 2024 | ₹710 Cr | ₹164 Cr | 28.5% |
| 2023 | ₹721 Cr | ₹160 Cr | 26.9% |
| 2022 | ₹678 Cr | ₹182 Cr | 33.5% |
| 2021 | ₹499 Cr | ₹136 Cr | 41.0% |
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and